Core Viewpoint - Terumo, a Japanese medical device manufacturer, is acquiring a German factory from WuXi Biologics for €150 million, aiming to establish its first overseas CDMO base and target large pharmaceutical orders in Europe by 2030 [1]. Group 1: Acquisition Details - The acquisition amount is €150 million, and the factory covers an area of 13,000 square meters [1]. - Approximately 150 employees will transition to Terumo following the acquisition [1]. - The factory is expected to produce pre-filled syringes, although the production capacity has not been disclosed [1]. Group 2: Strategic Goals - Terumo aims to leverage the German factory as a foothold for expanding its overseas operations, particularly targeting major pharmaceutical companies headquartered in Europe, such as Roche and Novartis [1]. - The company is actively developing its CDMO business to provide integrated solutions for drug-compatible containers and delivery devices [1]. - Terumo plans to enhance the production capacity of its Kofu factory in Yamanashi Prefecture within the fiscal year ending March 2025 [1]. Group 3: Market Position - Currently, Terumo's primary clients are domestic pharmaceutical companies in Japan, but it has secured its first overseas order in 2024 [1].
泰尔茂收购中国药明生物的德国工厂